Page last updated: 2024-12-07
4'-o-methyldoxorubicin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4'-O-methyldoxorubicin: RN given refers to parent cpd(L-lyxo)-(8S-cis)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 100443 |
CHEMBL ID | 3230576 |
MeSH ID | M0097097 |
Synonyms (8)
Synonym |
---|
4'-o-methyldoxorubicin |
77121-90-5 |
nsc 301477 |
5,12-naphthacenedione, (10-(3-amino-2,3,6-trideoxy-4-o-methyl-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8s-cis)- |
ccris 1432 |
3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-naphthacenyl 3-amino-2,3,6-trideoxy-4-o-methylhexopyranoside |
(7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-methoxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione |
CHEMBL3230576 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (6)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1123755 | Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as optimal dose | 1979 | Journal of medicinal chemistry, Feb, Volume: 22, Issue:2 | Synthesis and antitumor activity of 4'-O-methyldaunorubicin, 4'-O-methyladriamycin, and their 4'-epi analogues. |
AID1123764 | Antitumor activity against mouse L1210 cells allografted in mouse assessed as average survival time at 4.4 mg/kg, ip relative to untreated control | 1979 | Journal of medicinal chemistry, Feb, Volume: 22, Issue:2 | Synthesis and antitumor activity of 4'-O-methyldaunorubicin, 4'-O-methyladriamycin, and their 4'-epi analogues. |
AID1123765 | Antitumor activity against mouse L1210 cells allografted in mouse assessed as average survival time at 6.6 mg/kg, ip relative to untreated control | 1979 | Journal of medicinal chemistry, Feb, Volume: 22, Issue:2 | Synthesis and antitumor activity of 4'-O-methyldaunorubicin, 4'-O-methyladriamycin, and their 4'-epi analogues. |
AID1123762 | Toxicity in mouse allografted with mouse P388 cells at 6.6 mg/kg, ip | 1979 | Journal of medicinal chemistry, Feb, Volume: 22, Issue:2 | Synthesis and antitumor activity of 4'-O-methyldaunorubicin, 4'-O-methyladriamycin, and their 4'-epi analogues. |
AID1123766 | Antitumor activity against mouse L1210 cells allografted in mouse assessed as average survival time at 10 mg/kg, ip relative to untreated control | 1979 | Journal of medicinal chemistry, Feb, Volume: 22, Issue:2 | Synthesis and antitumor activity of 4'-O-methyldaunorubicin, 4'-O-methyladriamycin, and their 4'-epi analogues. |
AID1123758 | Antitumor activity against mouse P388 cells allografted in mouse assessed as average survival time at 6.6 mg/kg, ip relative to untreated control | 1979 | Journal of medicinal chemistry, Feb, Volume: 22, Issue:2 | Synthesis and antitumor activity of 4'-O-methyldaunorubicin, 4'-O-methyladriamycin, and their 4'-epi analogues. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (4)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |